JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB96861

Anti-Cullin 7/CUL-7 antibody

1

(1 Review)

|

(3 Publications)

Rabbit Polyclonal Cullin 7/CUL-7 antibody. Suitable for WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Synthetic Peptide within Human CUL7 aa 1350 to C-terminus.

View Alternative Names

KIAA0076, CUL7, Cullin-7, CUL-7

1 Images
Western blot - Anti-Cullin 7/CUL-7 antibody (AB96861)
  • WB

Unknown

Western blot - Anti-Cullin 7/CUL-7 antibody (AB96861)

A 7.5% SDS-PAGE gel was used.

All lanes:

Western blot - Anti-Cullin 7/CUL-7 antibody (ab96861) at 1/1000 dilution

All lanes:

Molt-4 cell lysate at 30 µg

Predicted band size: 191 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

Synthetic Peptide within Human CUL7 aa 1350 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

Q14999

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: 20% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Core component of the 3M and Cul7-RING(FBXW8) complexes, which mediate the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed : 12481031, PubMed : 12904573, PubMed : 21572988, PubMed : 21737058, PubMed : 24793695, PubMed : 35982156). Core component of the 3M complex, a complex required to regulate microtubule dynamics and genome integrity (PubMed : 21572988, PubMed : 21737058, PubMed : 24793695). It is unclear how the 3M complex regulates microtubules, it could act by controlling the level of a microtubule stabilizer (PubMed : 24793695). The Cul7-RING(FBXW8) complex alone lacks ubiquitination activity and does not promote polyubiquitination and proteasomal degradation of p53/TP53 (PubMed : 16547496, PubMed : 17332328, PubMed : 35982156). However it mediates recruitment of p53/TP53 for ubiquitination by neddylated CUL1-RBX1 (PubMed : 35982156). Interaction with CUL9 is required to inhibit CUL9 activity and ubiquitination of BIRC5 (PubMed : 24793696). The Cul7-RING(FBXW8) complex also mediates ubiquitination and consequent degradation of target proteins such as GORASP1, IRS1 and MAP4K1/HPK1 (PubMed : 21572988, PubMed : 24362026). Ubiquitination of GORASP1 regulates Golgi morphogenesis and dendrite patterning in brain (PubMed : 21572988). Mediates ubiquitination and degradation of IRS1 in a mTOR-dependent manner : the Cul7-RING(FBXW8) complex recognizes and binds IRS1 previously phosphorylated by S6 kinase (RPS6KB1 or RPS6KB2) (PubMed : 18498745). The Cul7-RING(FBXW8) complex also mediates ubiquitination of MAP4K1/HPK1 : recognizes and binds autophosphorylated MAP4K1/HPK1, leading to its degradation, thereby affecting cell proliferation and differentiation (PubMed : 24362026). Acts as a regulator in trophoblast cell epithelial-mesenchymal transition and placental development (PubMed : 20139075). While the Cul7-RING(FBXW8) and the 3M complexes are associated and involved in common processes, CUL7 and the Cul7-RING(FBXW8) complex may have additional functions. Probably plays a role in the degradation of proteins involved in endothelial proliferation and/or differentiation.
See full target information CUL7

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

Cell death and differentiation : PubMed33504946

2021

Tumor-associated antigen Prame targets tumor suppressor p14/ARF for degradation as the  receptor protein of CRL2 complex.

Applications

Unspecified application

Species

Unspecified reactive species

Wenjuan Zhang,Lihui Li,Lili Cai,Yupei Liang,Junfeng Xu,Yue Liu,Lisha Zhou,Chen Ding,Yanmei Zhang,Hu Zhao,Jun Qin,Zhimin Shao,Wenyi Wei,Lijun Jia

Nature communications 11:24 PubMed31911655

2020

The RepID-CRL4 ubiquitin ligase complex regulates metaphase to anaphase transition via BUB3 degradation.

Applications

Unspecified application

Species

Unspecified reactive species

Sang-Min Jang,Jenny F Nathans,Haiqing Fu,Christophe E Redon,Lisa M Jenkins,Bhushan L Thakur,Lőrinc S Pongor,Adrian M Baris,Jacob M Gross,Maura J OʹNeill,Fred E Indig,Steven D Cappell,Mirit I Aladjem

Nature communications 9:2782 PubMed30018425

2018

The replication initiation determinant protein (RepID) modulates replication by recruiting CUL4 to chromatin.

Applications

Unspecified application

Species

Unspecified reactive species

Sang-Min Jang,Ya Zhang,Koichi Utani,Haiqing Fu,Christophe E Redon,Anna B Marks,Owen K Smith,Catherine J Redmond,Adrian M Baris,Danielle A Tulchinsky,Mirit I Aladjem
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com